First human test of novel cancer vaccine begins
NCT ID NCT05492682
Summary
This is an early safety study testing a new cancer vaccine called PeptiCRAd-1, given alongside the immunotherapy drug pembrolizumab. It aims to see if this combination is safe and can activate the immune system to fight cancer in patients with advanced solid tumors that have stopped responding to standard treatments. The study will enroll 15 adults with specific cancer types, including melanoma, breast cancer, lung cancer, and sarcomas.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Krankenhaus Nordwest
Frankfurt, Germany
-
National Center for Tumor Diseases
Heidelberg, Germany
-
Universitätsklinikum Tübingen
Tübingen, Germany
Conditions
Explore the condition pages connected to this study.